NHI should cover Revlimid under risk-sharing agreements

Celgene Korea was in negotiations to agree a deal to make its cancer drug Revlimid more affordable to the National Health Insurance (NHI) last year, but failed to reverse a negative decision of the National Health Insurance Corporation.

The company is one of the first to take up the opportunity to negotiate under new 'risk-sharing deals', which are more known as 'patient-access schemes'. But...